Precision Dosing for Pulmonary Tuberculosis
Part of Infections, Lungs & breathing clinical trials.
This trial tests a personalized approach to dosing the TB medicine rifampin. By using a computer model based on your individual factors, doctors hope to find the right dose for you, which may improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have pulmonary tuberculosis (TB in your lungs) confirmed by a test.
- You are currently taking (or will start) a TB treatment that includes rifampin.
- You have been taking rifampin for 8 weeks or less.
- You have not received rifampin through an IV or been in the intensive care unit.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether higher or standard doses of the antibiotic rifampicin work better for treating pulmonary tuberculosis (a lung infection). You may benefit if you are starting TB treatment and have not had a bad reaction to rifampicin before.
This trial tests whether you can take a shorter course of standard treatment for drug-sensitive pulmonary (lung) tuberculosis by using a higher dose of rifampicin. It may help some people finish treatment sooner, while doctors track how well the infection clears.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This trial tests a shorter treatment for TB that is resistant to the drug rifampicin but still sensitive to isoniazid. It may help people finish treatment sooner and with fewer side effects.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.